/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
With a market cap of $116.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on developing and commercializing innovative therapies, best known for its leading portfolio of cystic fibrosis treatments including TRIKAFTA/KAFTRIO, ALYFTREK, and KALYDECO. It also advances medicines for serious diseases such as sickle cell disease, beta thalassemia, diabetes, kidney disease, and acute pain through a strong research pipeline and strategic collaborations.
The Boston, Massachusetts-based company is slated to announce its fiscal Q4 2025 results soon. Ahead of the event, analysts expect VRTX to report an adjusted EPS of $4.41, up 24.6% from $3.54 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarterly reports while missing on another occasion.
